Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 16, 2016
May 7, 2020
9f893e7b-4aa3-4e4f-81bb-b2d74e521f3e
Related Documents
Determining Whether to Submit an ANDA or a 505(b)(2) Application
Guidance DocumentMay 10, 2019Center for Drug Evaluation and Research
Botanical Drug Development: Guidance for Industry
Guidance DocumentDecember 29, 2016Center for Drug Evaluation and Research
Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry
Guidance DocumentFebruary 18, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox